Sunpan Biotechnology

Sunpan Biotechnology is a clinical-stage biopharmaceutical company based in Suzhou, China, specializing in the discovery and development of targeted protein degradation (TPD) therapies. The company leverages its proprietary PROTAC (Proteolysis Targeting Chimera) platform to create small molecule degraders that eliminate disease-causing proteins by utilizing the cell's natural ubiquitin-proteasome system. Its lead candidate, SP-002, is an orally available androgen receptor (AR) degrader currently in Phase 1 clinical trials for the treatment of metastatic castration-resistant prostate cancer. Sunpan's pipeline also includes programs targeting Bruton's tyrosine kinase (BTK) and GSPT1, aimed at addressing unmet needs in hematological malignancies and solid tumors.